CIMA Labs Catches The Eye Of Another As Cephalon Outbids AaiPharma
This article was originally published in The Tan Sheet
Executive Summary
AaiPharma's refusal to increase its offer for fast-dissolving drug delivery technology maker CIMA Labs puts into serious jeopardy their proposed merger in the face of a rival bid from Rx drug company Cephalon
You may also be interested in...
CIMA Shareholder Suits Follow Firm’s Rejection Of Cephalon Merger Offer
Two class action shareholder lawsuits filed after CIMA Labs rejected Cephalon's acquisition offer could complicate the firm's proposed merger with aaiPharma
CIMA Shareholder Suits Follow Firm’s Rejection Of Cephalon Merger Offer
Two class action shareholder lawsuits filed after CIMA Labs rejected Cephalon's acquisition offer could complicate the firm's proposed merger with aaiPharma
CIMA Shareholder Suits Follow Firm’s Rejection Of Cephalon Merger Offer
Two class action shareholder lawsuits filed after CIMA Labs rejected Cephalon's acquisition offer could complicate the firm's proposed merger with aaiPharma